ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma

Sponsor
Lymphoma Study Association
Study ID
NCT00140660
Phase
PHASE3
Status
Terminated

Conditions

  • Diffuse Large Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is a multicentric randomized trial evaluating the efficacy of the combination R-ACVBP in patients 18 to 65 years with low risk localized diffuse large B-cell lymphoma.

Key Dates

Start date
Dec 31, 2003
Status verified
Mar 2017
Primary completion
Jul 31, 2008
Completion
Apr 30, 2012

Study Design

Enrollment
223 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: R-ACVBP
    addition of rituximab to standard ACVBP chemotherapy
  • No Intervention: ACVBP
    standard ACVBP chemotherapy

Primary Outcome Measure

Event-free survival (EFS) [ Time Frame: 4 years ]

Related Studies